Cancelmo Peter B
Known title: VP, General CounselCIK: 0001778968
Associated companies
Transaction History
| OMER | ▲ Buy | Option Exercise | 25,000 | $74K | 8/31/2026 | View on chart |
| OMER | ▼ Sell | Open Market | 25,000 | $464K | 8/31/2026 | View on chart |
| OMER | ▲ Buy | Option Exercise | 25,000 | $74K | 8/28/2026 | View on chart |
| OMER | ▼ Sell | Open Market | 25,000 | $466K | 8/28/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Cantor Fitzgerald upgrades Omeros to Overweight with $22 target
Cantor Fitzgerald upgraded Omeros to Overweight and set a $22 price target, citing potential for its transplant drug. The stock recently hit a five-year peak, reflecting growing investor interest. This move aligns with broader analyst optimism, as the average target price stands at $27.50.
Cantor Fitzgerald upgrades Omeros to Overweight with $22 target. Cantor Fitzgerald upgraded Omeros to Overweight and set a $22 price target, citing potential for its transplant drug. The stock recently hit a five-year peak, reflecting growing investor interest. This move aligns with broader analyst optimism, as the average target price stands at $27.50.